ORIGINAL ARTICLE
Ahead of Print

Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer


1 School of Life Sciences, Anhui University, Hefei, China
2 Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, California, USA
3 Department of Urology, The First Affiliated Hospital of SooChow University, Suzhou, China
4 Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
5 Department of Pathology, Beijing Hospital, Beijing, China

Correspondence Address:
Jiao-Ti Huang,
Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, California, USA

Min Zhang,
School of Life Sciences, Anhui University, Hefei, China

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Although adenocarcinomas of the prostate are relatively indolent, some patients with advanced adenocarcinomas show recurrence of treatment-induced neuroendocrine prostate cancer, which is highly aggressive and lethal. Detailed biological features of treatment-induced neuroendocrine prostate cancer have not been characterized owing to limited biopsies/resections and the lack of a cellular model. In this study, we used a unique cellular model (LNCaP/NE1.8) to investigate the potential role of cancer stem cells in treatment-induced neuroendocrine prostate cancer with acquired resistance to hormonal therapy and chemotherapy. We also studied the role of cancer stem cells in enhancing invasion in treatment-induced neuroendocrine prostate cancer cells that recurred after long-term androgen-ablation treatment. Using an in vitro system mimicking clinical androgen-ablation, our results showed that the neuroendocrine-like subclone NE1.8 cells were enriched with cancer stem cells. Compared to parental prostate adenocarcinoma LNCaP cells, NE1.8 cells are more resistant to androgen deprivation therapy and chemotherapeutic agents and show increased cancer cell invasiveness. Results from this study also suggest a potential epigenetic therapeutic strategy using suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, as a chemotherapeutic agent for therapy-resistant treatment-induced neuroendocrine prostate cancer cells to minimize the risk of prostate cancer recurrence and metastasis.


[FULL TEXT] [PDF]
Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Xu X
    -  Huang YH
    -  Li YJ
    -  Cohen A
    -  Li Z
    -  Squires J
    -  Zhang W
    -  Chen XF
    -  Zhang M
    -  Huang JT
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed426    
    PDF Downloaded65    

Recommend this journal